ID   PKN1_HUMAN              Reviewed;         942 AA.
AC   Q16512; A8K7W5; B2R9R4; B3KVN3; Q15143; Q504U4; Q8IUV5; Q9UD44;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 2.
DT   10-MAY-2017, entry version 197.
DE   RecName: Full=Serine/threonine-protein kinase N1;
DE            EC=2.7.11.13 {ECO:0000269|PubMed:18066052};
DE   AltName: Full=Protease-activated kinase 1;
DE            Short=PAK-1;
DE   AltName: Full=Protein kinase C-like 1;
DE   AltName: Full=Protein kinase C-like PKN;
DE   AltName: Full=Protein kinase PKN-alpha;
DE   AltName: Full=Protein-kinase C-related kinase 1;
DE   AltName: Full=Serine-threonine protein kinase N;
GN   Name=PKN1; Synonyms=PAK1, PKN, PRK1, PRKCL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-644.
RC   TISSUE=Hippocampus;
RX   PubMed=8135837; DOI=10.1006/bbrc.1994.1313;
RA   Mukai H., Ono Y.;
RT   "A novel protein kinase with leucine zipper-like sequences: its
RT   catalytic domain is highly homologous to that of protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 199:897-904(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=7851406; DOI=10.1111/j.1432-1033.1995.tb20395.x;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Cloning and expression patterns of two members of a novel protein-
RT   kinase-C-related kinase family.";
RL   Eur. J. Biochem. 227:344-351(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS ILE-555 AND ILE-901.
RC   TISSUE=Kidney, Synovium, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   ILE-901.
RC   TISSUE=Brain, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 700-800 (ISOFORMS 1/2), AND VARIANT
RP   VAL-718.
RX   PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Identification of multiple, novel, protein kinase C-related gene
RT   products.";
RL   FEBS Lett. 356:5-8(1994).
RN   [7]
RP   FUNCTION.
RX   PubMed=8557118; DOI=10.1016/0014-5793(95)01454-3;
RA   Palmer R.H., Schonwasser D.C., Rahman D., Pappin D.J., Herget T.,
RA   Parker P.J.;
RT   "PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156
RT   and serine 163.";
RL   FEBS Lett. 378:281-285(1996).
RN   [8]
RP   FUNCTION.
RX   PubMed=8621664; DOI=10.1074/jbc.271.16.9816;
RA   Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M.,
RA   Miyahara M., Sunakawa H., Ono Y.;
RT   "PKN associates and phosphorylates the head-rod domain of
RT   neurofilament protein.";
RL   J. Biol. Chem. 271:9816-9822(1996).
RN   [9]
RP   ENZYME REGULATION, AND INTERACTION WITH RHOA.
RX   PubMed=8571126; DOI=10.1126/science.271.5249.645;
RA   Watanabe G., Saito Y., Madaule P., Ishizaki T., Fujisawa K., Morii N.,
RA   Mukai H., Ono Y., Kakizuka A., Narumiya S.;
RT   "Protein kinase N (PKN) and PKN-related protein rhophilin as targets
RT   of small GTPase Rho.";
RL   Science 271:645-648(1996).
RN   [10]
RP   FUNCTION.
RX   PubMed=9175763; DOI=10.1006/bbrc.1997.6669;
RA   Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y.,
RA   Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.;
RT   "Domain-specific phosphorylation of vimentin and glial fibrillary
RT   acidic protein by PKN.";
RL   Biochem. Biophys. Res. Commun. 234:621-625(1997).
RN   [11]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH RHOB.
RX   PubMed=9478917; DOI=10.1074/jbc.273.9.4811;
RA   Mellor H., Flynn P., Nobes C.D., Hall A., Parker P.J.;
RT   "PRK1 is targeted to endosomes by the small GTPase, RhoB.";
RL   J. Biol. Chem. 273:4811-4814(1998).
RN   [12]
RP   ENZYME REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-108;
RP   ASP-451; ASP-454; ASP-558 AND ASP-560.
RX   PubMed=9751706; DOI=10.1073/pnas.95.20.11566;
RA   Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y.;
RT   "Proteolytic activation of PKN by caspase-3 or related protease during
RT   apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11566-11571(1998).
RN   [13]
RP   PHOSPHORYLATION AT THR-774 BY PDPK1, AND INTERACTION WITH PDPK1.
RX   PubMed=10792047; DOI=10.1073/pnas.090491897;
RA   Dong L.Q., Landa L.R., Wick M.J., Zhu L., Mukai H., Ono Y., Liu F.;
RT   "Phosphorylation of protein kinase N by phosphoinositide-dependent
RT   protein kinase-1 mediates insulin signals to the actin cytoskeleton.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:5089-5094(2000).
RN   [14]
RP   FUNCTION.
RX   PubMed=11104762; DOI=10.1074/jbc.M007427200;
RA   Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T.,
RA   Yasuda M., Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y.,
RA   Tanaka C.;
RT   "Phosphorylation of tau is regulated by PKN.";
RL   J. Biol. Chem. 276:10025-10031(2001).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ANDR.
RX   PubMed=12514133; DOI=10.1093/emboj/cdg023;
RA   Metzger E., Muller J.M., Ferrari S., Buettner R., Schule R.;
RT   "A novel inducible transactivation domain in the androgen receptor:
RT   implications for PRK in prostate cancer.";
RL   EMBO J. 22:270-280(2003).
RN   [16]
RP   INTERACTION WITH S.TYPHIMURIUM SSPH1 (MICROBIAL INFECTION).
RX   PubMed=16611232; DOI=10.1111/j.1462-5822.2005.00670.x;
RA   Haraga A., Miller S.I.;
RT   "A Salmonella type III secretion effector interacts with the mammalian
RT   serine/threonine protein kinase PKN1.";
RL   Cell. Microbiol. 8:837-846(2006).
RN   [17]
RP   INTERACTION WITH CCNT2.
RX   PubMed=16331689; DOI=10.1002/jcp.20566;
RA   Cottone G., Baldi A., Palescandolo E., Manente L., Penta R.,
RA   Paggi M.G., De Luca A.;
RT   "Pkn is a novel partner of cyclin T2a in muscle differentiation.";
RL   J. Cell. Physiol. 207:232-237(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533 AND SER-562, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [19]
RP   FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=17332740; DOI=10.1038/sj.emboj.7601637;
RA   Schmidt A., Durgan J., Magalhaes A., Hall A.;
RT   "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit
RT   from cytokinesis.";
RL   EMBO J. 26:1624-1636(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-778, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND SER-537, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-644.
RX   PubMed=18066052; DOI=10.1038/ncb1668;
RA   Metzger E., Yin N., Wissmann M., Kunowska N., Fischer K.,
RA   Friedrichs N., Patnaik D., Higgins J.M., Potier N., Scheidtmann K.H.,
RA   Buettner R., Schule R.;
RT   "Phosphorylation of histone H3 at threonine 11 establishes a novel
RT   chromatin mark for transcriptional regulation.";
RL   Nat. Cell Biol. 10:53-60(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537; SER-559;
RP   SER-562 AND SER-916, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-533; SER-537;
RP   SER-559; SER-562; THR-914 AND SER-916, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-448, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [27]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057;
RA   Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B.,
RA   McKinsey T.A.;
RT   "Protein kinase C-related kinase targets nuclear localization signals
RT   in a subset of class IIa histone deacetylases.";
RL   FEBS Lett. 584:1103-1110(2010).
RN   [28]
RP   INTERACTION WITH PRKCB.
RX   PubMed=20228790; DOI=10.1038/nature08839;
RA   Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N.,
RA   Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N.,
RA   Beisenherz-Huss C., Gunther T., Buettner R., Schule R.;
RT   "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation
RT   at histone H3K4.";
RL   Nature 464:792-796(2010).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537 AND
RP   SER-562, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; MAPK14; ZAK AND
RP   MAP2K3.
RX   PubMed=21224381; DOI=10.1074/jbc.M110.185645;
RA   Cariolato L., Cavin S., Diviani D.;
RT   "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling
RT   complex involved in alpha1-adrenergic receptor-induced p38
RT   activation.";
RL   J. Biol. Chem. 286:7925-7937(2011).
RN   [32]
RP   FUNCTION IN CELL MIGRATION, AND TISSUE SPECIFICITY.
RX   PubMed=21754995; DOI=10.1371/journal.pone.0021732;
RA   Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S.,
RA   Collazos A., Parker P.J.;
RT   "Regulatory domain selectivity in the cell-type specific PKN-
RT   dependence of cell migration.";
RL   PLoS ONE 6:E21732-E21732(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69; SER-533; SER-537;
RP   SER-540; SER-562; SER-608 AND SER-916, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-916, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98 IN COMPLEX WITH RHOA.
RX   PubMed=10619026; DOI=10.1016/S1097-2765(00)80389-5;
RA   Maesaki R., Ihara K., Shimizu T., Kuroda S., Kaibuchi K.,
RA   Hakoshima T.;
RT   "The structural basis of Rho effector recognition revealed by the
RT   crystal structure of human RhoA complexed with the effector domain of
RT   PKN/PRK1.";
RL   Mol. Cell 4:793-803(1999).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98.
RX   PubMed=10388627; DOI=10.1006/jsbi.1999.4114;
RA   Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K.,
RA   Hakoshima T.;
RT   "Biochemical and crystallographic characterization of a Rho effector
RT   domain of the protein serine/threonine kinase N in a complex with
RT   RhoA.";
RL   J. Struct. Biol. 126:166-170(1999).
RN   [39]
RP   STRUCTURE BY NMR OF 116-199 IN COMPLEX WITH RAC1.
RX   PubMed=14514689; DOI=10.1074/jbc.M304313200;
RA   Owen D., Lowe P.N., Nietlispach D., Brosnan C.E., Chirgadze D.Y.,
RA   Parker P.J., Blundell T.L., Mott H.R.;
RT   "Molecular dissection of the interaction between the small G proteins
RT   Rac1 and RhoA and protein kinase C-related kinase 1 (PRK1).";
RL   J. Biol. Chem. 278:50578-50587(2003).
RN   [40]
RP   STRUCTURE BY NMR OF 122-199 IN COMPLEX WITH RAC1.
RX   PubMed=18006505; DOI=10.1074/jbc.M706760200;
RA   Modha R., Campbell L.J., Nietlispach D., Buhecha H.R., Owen D.,
RA   Mott H.R.;
RT   "The Rac1 polybasic region is required for interaction with its
RT   effector PRK1.";
RL   J. Biol. Chem. 283:1492-1500(2008).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 122-199 IN COMPLEX WITH
RP   SALMONELLA SSPH1, UBIQUITINATION (MICROBIAL INFECTION), MUTAGENESIS OF
RP   ARG-181 AND ARG-185, FUNCTION AS ANDROGEN RECEPTOR COACTIVATOR, AND
RP   INTERACTION WITH SALMONELLA SSPH1 (MICROBIAL INFECTION).
RX   PubMed=24248594; DOI=10.1128/MCB.01360-13;
RA   Keszei A.F., Tang X., McCormick C., Zeqiraj E., Rohde J.R., Tyers M.,
RA   Sicheri F.;
RT   "Structure of an SspH1-PKN1 complex reveals the basis for host
RT   substrate recognition and mechanism of activation for a bacterial E3
RT   ubiquitin ligase.";
RL   Mol. Cell. Biol. 34:362-373(2014).
RN   [42]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-185; GLU-197; TRP-436; GLN-520;
RP   ILE-555; GLN-635; VAL-718; LEU-873; ILE-901 AND VAL-921.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: PKC-related serine/threonine-protein kinase involved in
CC       various processes such as regulation of the intermediate filaments
CC       of the actin cytoskeleton, cell migration, tumor cell invasion and
CC       transcription regulation. Part of a signaling cascade that begins
CC       with the activation of the adrenergic receptor ADRA1B and leads to
CC       the activation of MAPK14. Regulates the cytoskeletal network by
CC       phosphorylating proteins such as VIM and neurofilament proteins
CC       NEFH, NEFL and NEFM, leading to inhibit their polymerization.
CC       Phosphorylates 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau,
CC       lowering its ability to bind to microtubules, resulting in
CC       disruption of tubulin assembly. Acts as a key coactivator of
CC       androgen receptor (ANDR)-dependent transcription, by being
CC       recruited to ANDR target genes and specifically mediating
CC       phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific
CC       tag for epigenetic transcriptional activation that promotes
CC       demethylation of histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C.
CC       Phosphorylates HDAC5, HDAC7 and HDAC9, leading to impair their
CC       import in the nucleus. Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-
CC       159', 'Ser-163' and 'Ser-170' of MARCKS, and GFAP. Able to
CC       phosphorylate RPS6 in vitro. {ECO:0000269|PubMed:11104762,
CC       ECO:0000269|PubMed:12514133, ECO:0000269|PubMed:17332740,
CC       ECO:0000269|PubMed:18066052, ECO:0000269|PubMed:20188095,
CC       ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:21754995,
CC       ECO:0000269|PubMed:24248594, ECO:0000269|PubMed:8557118,
CC       ECO:0000269|PubMed:8621664, ECO:0000269|PubMed:9175763}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:18066052}.
CC   -!- ENZYME REGULATION: Kinase activity is activated upon binding to
CC       Rho proteins (RHOA, RHOB and RAC1). Activated by lipids,
CC       particularly cardiolipin and to a lesser extent by other acidic
CC       phospholipids. Activated by caspase-3 (CASP3) cleavage during
CC       apoptosis. Two specific sites, Thr-774 (activation loop of the
CC       kinase domain) and Ser-916 (turn motif), need to be phosphorylated
CC       for its full activation. {ECO:0000269|PubMed:8571126,
CC       ECO:0000269|PubMed:9751706}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=20.6 uM for HDAC5 {ECO:0000269|PubMed:20188095};
CC   -!- SUBUNIT: Interacts with ZFAND6 (By similarity). Interacts with
CC       ANDR (PubMed:12514133). Interacts with PRKCB (PubMed:20228790).
CC       Interacts (via REM 1 and REM 2 repeats) with RAC1
CC       (PubMed:14514689, PubMed:18006505). Interacts (via REM 1 repeat)
CC       with RHOA (PubMed:10619026, PubMed:8571126). Interacts with RHOB
CC       (PubMed:9478917). Interacts (via C-terminus) with PDPK1
CC       (PubMed:10792047). Interacts with CCNT2; enhances MYOD1-dependent
CC       transcription (PubMed:16331689). Component of a signaling complex
CC       containing at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within
CC       this complex, AKAP13 interacts directly with PKN1, which in turn
CC       recruits MAPK14, MAP2K3 and ZAK (PubMed:21224381).
CC       {ECO:0000250|UniProtKB:P70268, ECO:0000269|PubMed:10619026,
CC       ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:12514133,
CC       ECO:0000269|PubMed:14514689, ECO:0000269|PubMed:16331689,
CC       ECO:0000269|PubMed:18006505, ECO:0000269|PubMed:20228790,
CC       ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8571126,
CC       ECO:0000269|PubMed:9478917}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via the second REM
CC       repeat) with S.typhimurium E3 ubiquitin-protein ligase SspH1 (via
CC       the leucine-rich repeat region) (PubMed:16611232,
CC       PubMed:24248594). {ECO:0000269|PubMed:16611232,
CC       ECO:0000269|PubMed:24248594}.
CC   -!- INTERACTION:
CC       Q15834:CCDC85B; NbExp=2; IntAct=EBI-602382, EBI-739674;
CC       Q01850:CDR2; NbExp=5; IntAct=EBI-602382, EBI-1181367;
CC       Q8IYX8-2:CEP57L1; NbExp=3; IntAct=EBI-602382, EBI-10181988;
CC       Q08379:GOLGA2; NbExp=3; IntAct=EBI-602382, EBI-618309;
CC       B2RA10:HOMER3; NbExp=3; IntAct=EBI-602382, EBI-10175777;
CC       Q9NSC5:HOMER3; NbExp=3; IntAct=EBI-602382, EBI-748420;
CC       P19012:KRT15; NbExp=3; IntAct=EBI-602382, EBI-739566;
CC       Q15323:KRT31; NbExp=5; IntAct=EBI-602382, EBI-948001;
CC       P53778:MAPK12; NbExp=2; IntAct=EBI-602382, EBI-602406;
CC       O15344:MID1; NbExp=3; IntAct=EBI-602382, EBI-2340316;
CC       Q9Y2D8:SSX2IP; NbExp=3; IntAct=EBI-602382, EBI-2212028;
CC       P08670:VIM; NbExp=3; IntAct=EBI-602382, EBI-353844;
CC       Q9NYL2-1:ZAK; NbExp=2; IntAct=EBI-602382, EBI-687346;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17332740,
CC       ECO:0000269|PubMed:9478917}. Nucleus
CC       {ECO:0000269|PubMed:12514133}. Endosome
CC       {ECO:0000269|PubMed:9478917}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q63433}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q63433}. Cleavage furrow
CC       {ECO:0000269|PubMed:17332740}. Midbody
CC       {ECO:0000269|PubMed:17332740}. Note=Associates with chromatin in a
CC       ligand-dependent manner. Localization to endosomes is mediated via
CC       its interaction with RHOB. Association to the cell membrane is
CC       dependent on Ser-377 phosphorylation. Accumulates during telophase
CC       at the cleavage furrow and finally concentrates around the midbody
CC       in cytokinesis. {ECO:0000250|UniProtKB:Q63433,
CC       ECO:0000269|PubMed:17332740}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q16512-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16512-2; Sequence=VSP_038143;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain,
CC       placenta, lung, skeletal muscle, kidney and pancreas. Expressed in
CC       numerous tumor cell lines, especially in breast tumor cells.
CC       {ECO:0000269|PubMed:21754995}.
CC   -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).
CC   -!- PTM: Autophosphorylated; preferably on serine. Phosphorylated
CC       during mitosis. {ECO:0000269|PubMed:10792047,
CC       ECO:0000269|PubMed:17332740}.
CC   -!- PTM: Activated by limited proteolysis with trypsin. {ECO:0000250}.
CC   -!- PTM: (Microbial infection) In case of infection, polyubiquitinated
CC       by the bacterial E3 ubiquitin-protein ligase SspH1, leading to its
CC       proteasomal degradation. {ECO:0000269|PubMed:24248594}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D26181; BAA05169.1; -; mRNA.
DR   EMBL; S75546; AAB33345.1; -; mRNA.
DR   EMBL; U33053; AAC50209.1; -; mRNA.
DR   EMBL; AK123007; BAG53845.1; -; mRNA.
DR   EMBL; AK292130; BAF84819.1; -; mRNA.
DR   EMBL; AK313886; BAG36611.1; -; mRNA.
DR   EMBL; AC008569; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC040061; AAH40061.1; -; mRNA.
DR   EMBL; BC094766; AAH94766.1; -; mRNA.
DR   CCDS; CCDS42513.1; -. [Q16512-1]
DR   CCDS; CCDS42514.1; -. [Q16512-2]
DR   PIR; JC2129; JC2129.
DR   PIR; S51162; S51162.
DR   RefSeq; NP_002732.3; NM_002741.3. [Q16512-1]
DR   RefSeq; NP_998725.1; NM_213560.1. [Q16512-2]
DR   UniGene; Hs.466044; -.
DR   PDB; 1CXZ; X-ray; 2.20 A; B=13-98.
DR   PDB; 1URF; NMR; -; A=122-199.
DR   PDB; 2RMK; NMR; -; B=122-199.
DR   PDB; 4NKG; X-ray; 2.90 A; B/D=122-199.
DR   PDB; 4OTD; X-ray; 2.00 A; A=605-942.
DR   PDB; 4OTG; X-ray; 2.60 A; A=605-942.
DR   PDB; 4OTH; X-ray; 1.80 A; A=605-942.
DR   PDB; 4OTI; X-ray; 1.93 A; A=605-942.
DR   PDBsum; 1CXZ; -.
DR   PDBsum; 1URF; -.
DR   PDBsum; 2RMK; -.
DR   PDBsum; 4NKG; -.
DR   PDBsum; 4OTD; -.
DR   PDBsum; 4OTG; -.
DR   PDBsum; 4OTH; -.
DR   PDBsum; 4OTI; -.
DR   ProteinModelPortal; Q16512; -.
DR   SMR; Q16512; -.
DR   BioGrid; 111571; 63.
DR   DIP; DIP-34240N; -.
DR   IntAct; Q16512; 69.
DR   MINT; MINT-118694; -.
DR   STRING; 9606.ENSP00000343325; -.
DR   BindingDB; Q16512; -.
DR   ChEMBL; CHEMBL3384; -.
DR   GuidetoPHARMACOLOGY; 1520; -.
DR   iPTMnet; Q16512; -.
DR   PhosphoSitePlus; Q16512; -.
DR   BioMuta; PKN1; -.
DR   DMDM; 259016304; -.
DR   EPD; Q16512; -.
DR   MaxQB; Q16512; -.
DR   PaxDb; Q16512; -.
DR   PeptideAtlas; Q16512; -.
DR   PRIDE; Q16512; -.
DR   DNASU; 5585; -.
DR   Ensembl; ENST00000242783; ENSP00000242783; ENSG00000123143. [Q16512-1]
DR   Ensembl; ENST00000342216; ENSP00000343325; ENSG00000123143. [Q16512-2]
DR   GeneID; 5585; -.
DR   KEGG; hsa:5585; -.
DR   UCSC; uc002myp.4; human. [Q16512-1]
DR   CTD; 5585; -.
DR   DisGeNET; 5585; -.
DR   GeneCards; PKN1; -.
DR   H-InvDB; HIX0027472; -.
DR   HGNC; HGNC:9405; PKN1.
DR   HPA; CAB010278; -.
DR   HPA; HPA003982; -.
DR   MIM; 601032; gene.
DR   neXtProt; NX_Q16512; -.
DR   OpenTargets; ENSG00000123143; -.
DR   PharmGKB; PA33769; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00820000126964; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; Q16512; -.
DR   KO; K06071; -.
DR   OMA; EFRSSGE; -.
DR   OrthoDB; EOG091G00YT; -.
DR   PhylomeDB; Q16512; -.
DR   TreeFam; TF102005; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3.
DR   SignaLink; Q16512; -.
DR   SIGNOR; Q16512; -.
DR   ChiTaRS; PKN1; human.
DR   EvolutionaryTrace; Q16512; -.
DR   GeneWiki; Protein_kinase_N1; -.
DR   GenomeRNAi; 5585; -.
DR   PMAP-CutDB; Q16512; -.
DR   PRO; PR:Q16512; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000123143; -.
DR   CleanEx; HS_PKN1; -.
DR   ExpressionAtlas; Q16512; baseline and differential.
DR   Genevisible; Q16512; HS.
DR   GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0050681; F:androgen receptor binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0017049; F:GTP-Rho binding; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB.
DR   GO; GO:0035402; F:histone kinase activity (H3-T11 specific); IDA:UniProtKB.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004697; F:protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048365; F:Rac GTPase binding; IDA:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; TAS:ProtInc.
DR   GO; GO:0001783; P:B cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl.
DR   GO; GO:0010631; P:epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0035407; P:histone H3-T11 phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0002634; P:regulation of germinal center formation; IEA:Ensembl.
DR   GO; GO:0002637; P:regulation of immunoglobulin production; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0003014; P:renal system process; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011072; HR1_rho-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF02185; HR1; 3.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00742; Hr1; 3.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF46585; SSF46585; 3.
DR   SUPFAM; SSF49562; SSF49562; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell membrane; Chromatin regulator; Complete proteome; Cytoplasm;
KW   Endosome; Kinase; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    942       Serine/threonine-protein kinase N1.
FT                                /FTId=PRO_0000055719.
FT   REPEAT       34    110       REM 1.
FT   REPEAT      123    209       REM 2.
FT   REPEAT      210    291       REM 3.
FT   DOMAIN      325    461       C2.
FT   DOMAIN      615    874       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      875    942       AGC-kinase C-terminal.
FT   NP_BIND     621    629       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      181    185       Important for interaction with bacterial
FT                                SspH1 and SspH1-mediated
FT                                polyubiquitination.
FT                                {ECO:0000269|PubMed:24248594}.
FT   ACT_SITE    740    740       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     644    644       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        108    109       Cleavage; by caspase-3.
FT   SITE        454    455       Cleavage; by caspase-3.
FT   SITE        558    559       Cleavage; by caspase-3.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES      69     69       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     205    205       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES     374    374       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63433}.
FT   MOD_RES     448    448       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     533    533       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     537    537       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     540    540       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     559    559       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES     562    562       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     608    608       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     774    774       Phosphothreonine; by PDPK1.
FT                                {ECO:0000269|PubMed:10792047}.
FT   MOD_RES     778    778       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18220336}.
FT   MOD_RES     914    914       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     916    916       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1      7       MASDAVQ -> MAEANNPSEQELE (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038143.
FT   VAR_SEQ     603    603       S -> R (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039213.
FT   VAR_SEQ     604    942       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039214.
FT   VARIANT     185    185       R -> C (in a metastatic melanoma sample;
FT                                somatic mutation; dbSNP:rs267605306).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042337.
FT   VARIANT     197    197       A -> E. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042338.
FT   VARIANT     436    436       R -> W (in dbSNP:rs35132656).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042339.
FT   VARIANT     520    520       R -> Q (in dbSNP:rs56273055).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042340.
FT   VARIANT     555    555       L -> I (in dbSNP:rs34309238).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042341.
FT   VARIANT     635    635       R -> Q (in dbSNP:rs35416389).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042342.
FT   VARIANT     718    718       I -> V (in dbSNP:rs2230539).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:7988719}.
FT                                /FTId=VAR_042343.
FT   VARIANT     873    873       F -> L (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042344.
FT   VARIANT     901    901       V -> I (in dbSNP:rs10846).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_014937.
FT   VARIANT     921    921       A -> V (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042345.
FT   MUTAGEN     108    108       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of AF1 fragment.
FT                                {ECO:0000269|PubMed:9751706}.
FT   MUTAGEN     181    181       R->A: Abolishes interaction with
FT                                bacterial SspH1.
FT                                {ECO:0000269|PubMed:24248594}.
FT   MUTAGEN     181    181       R->K: Decreases interaction with
FT                                bacterial SspH1.
FT                                {ECO:0000269|PubMed:24248594}.
FT   MUTAGEN     185    185       R->A: Abolishes interaction with
FT                                bacterial SspH1.
FT                                {ECO:0000269|PubMed:24248594}.
FT   MUTAGEN     451    451       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of 70 kDa fragment.
FT                                {ECO:0000269|PubMed:9751706}.
FT   MUTAGEN     454    454       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of 70 kDa fragment.
FT                                {ECO:0000269|PubMed:9751706}.
FT   MUTAGEN     558    558       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of AF3 fragment.
FT                                {ECO:0000269|PubMed:9751706}.
FT   MUTAGEN     560    560       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of AF3 fragment.
FT                                {ECO:0000269|PubMed:9751706}.
FT   MUTAGEN     644    644       K->E: Abolishes Serine/threonine-protein
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:18066052,
FT                                ECO:0000269|PubMed:8135837}.
FT   MUTAGEN     644    644       K->R: Substantial reduction of
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:18066052,
FT                                ECO:0000269|PubMed:8135837}.
FT   CONFLICT    191    191       G -> D (in Ref. 2; AAB33345/AAC50209).
FT                                {ECO:0000305}.
FT   CONFLICT    562    562       S -> P (in Ref. 3; BAG36611).
FT                                {ECO:0000305}.
FT   CONFLICT    736    736       I -> T (in Ref. 6; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    750    750       T -> A (in Ref. 6; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    800    800       G -> A (in Ref. 6; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    812    812       E -> G (in Ref. 3; BAG36611).
FT                                {ECO:0000305}.
FT   CONFLICT    887    887       L -> P (in Ref. 3; BAG53845).
FT                                {ECO:0000305}.
FT   HELIX        15     18       {ECO:0000244|PDB:1CXZ}.
FT   HELIX        29     66       {ECO:0000244|PDB:1CXZ}.
FT   HELIX        71     95       {ECO:0000244|PDB:1CXZ}.
FT   TURN        122    124       {ECO:0000244|PDB:1URF}.
FT   HELIX       126    151       {ECO:0000244|PDB:4NKG}.
FT   TURN        157    159       {ECO:0000244|PDB:4NKG}.
FT   HELIX       160    187       {ECO:0000244|PDB:4NKG}.
FT   STRAND      194    196       {ECO:0000244|PDB:2RMK}.
FT   HELIX       612    614       {ECO:0000244|PDB:4OTH}.
FT   STRAND      615    624       {ECO:0000244|PDB:4OTH}.
FT   STRAND      627    634       {ECO:0000244|PDB:4OTH}.
FT   TURN        635    637       {ECO:0000244|PDB:4OTH}.
FT   STRAND      640    647       {ECO:0000244|PDB:4OTH}.
FT   HELIX       648    653       {ECO:0000244|PDB:4OTH}.
FT   HELIX       657    671       {ECO:0000244|PDB:4OTH}.
FT   TURN        672    674       {ECO:0000244|PDB:4OTG}.
FT   STRAND      681    686       {ECO:0000244|PDB:4OTH}.
FT   STRAND      688    696       {ECO:0000244|PDB:4OTH}.
FT   STRAND      700    702       {ECO:0000244|PDB:4OTH}.
FT   HELIX       703    706       {ECO:0000244|PDB:4OTH}.
FT   TURN        707    709       {ECO:0000244|PDB:4OTH}.
FT   HELIX       714    733       {ECO:0000244|PDB:4OTH}.
FT   HELIX       743    745       {ECO:0000244|PDB:4OTH}.
FT   STRAND      746    748       {ECO:0000244|PDB:4OTH}.
FT   STRAND      750    752       {ECO:0000244|PDB:4OTG}.
FT   STRAND      754    756       {ECO:0000244|PDB:4OTH}.
FT   STRAND      763    765       {ECO:0000244|PDB:4OTD}.
FT   HELIX       779    781       {ECO:0000244|PDB:4OTD}.
FT   HELIX       784    788       {ECO:0000244|PDB:4OTD}.
FT   HELIX       794    810       {ECO:0000244|PDB:4OTH}.
FT   HELIX       820    829       {ECO:0000244|PDB:4OTH}.
FT   HELIX       840    849       {ECO:0000244|PDB:4OTH}.
FT   TURN        854    856       {ECO:0000244|PDB:4OTH}.
FT   TURN        862    864       {ECO:0000244|PDB:4OTH}.
FT   HELIX       865    869       {ECO:0000244|PDB:4OTH}.
FT   HELIX       872    874       {ECO:0000244|PDB:4OTH}.
FT   HELIX       879    883       {ECO:0000244|PDB:4OTH}.
FT   HELIX       906    909       {ECO:0000244|PDB:4OTH}.
FT   HELIX       926    930       {ECO:0000244|PDB:4OTH}.
FT   TURN        931    934       {ECO:0000244|PDB:4OTH}.
SQ   SEQUENCE   942 AA;  103932 MW;  61360295EC70BB8E CRC64;
     MASDAVQSEP RSWSLLEQLG LAGADLAAPG VQQQLELERE RLRREIRKEL KLKEGAENLR
     RATTDLGRSL GPVELLLRGS SRRLDLLHQQ LQELHAHVVL PDPAATHDGP QSPGAGGPTC
     SATNLSRVAG LEKQLAIELK VKQGAENMIQ TYSNGSTKDR KLLLTAQQML QDSKTKIDII
     RMQLRRALQA GQLENQAAPD DTQGSPDLGA VELRIEELRH HFRVEHAVAE GAKNVLRLLS
     AAKAPDRKAV SEAQEKLTES NQKLGLLREA LERRLGELPA DHPKGRLLRE ELAAASSAAF
     STRLAGPFPA THYSTLCKPA PLTGTLEVRV VGCRDLPETI PWNPTPSMGG PGTPDSRPPF
     LSRPARGLYS RSGSLSGRSS LKAEAENTSE VSTVLKLDNT VVGQTSWKPC GPNAWDQSFT
     LELERARELE LAVFWRDQRG LCALKFLKLE DFLDNERHEV QLDMEPQGCL VAEVTFRNPV
     IERIPRLRRQ KKIFSKQQGK AFQRARQMNI DVATWVRLLR RLIPNATGTG TFSPGASPGS
     EARTTGDISV EKLNLGTDSD SSPQKSSRDP PSSPSSLSSP IQESTAPELP SETQETPGPA
     LCSPLRKSPL TLEDFKFLAV LGRGHFGKVL LSEFRPSGEL FAIKALKKGD IVARDEVESL
     MCEKRILAAV TSAGHPFLVN LFGCFQTPEH VCFVMEYSAG GDLMLHIHSD VFSEPRAIFY
     SACVVLGLQF LHEHKIVYRD LKLDNLLLDT EGYVKIADFG LCKEGMGYGD RTSTFCGTPE
     FLAPEVLTDT SYTRAVDWWG LGVLLYEMLV GESPFPGDDE EEVFDSIVND EVRYPRFLSA
     EAIGIMRRLL RRNPERRLGS SERDAEDVKK QPFFRTLGWE ALLARRLPPP FVPTLSGRTD
     VSNFDEEFTG EAPTLSPPRD ARPLTAAEQA AFLDFDFVAG GC
//
